Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
Authors:
Open Access
- 3 November 2023
- journal article
- review article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 43, 100511
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancerCell Death & Disease, 2013
- The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related DiseasesInternational Journal of Biological Sciences, 2013
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell linesOncogenesis, 2012
- An overview of the c-MET signaling pathwayTherapeutic Advances in Medical Oncology, 2011
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcomaCancer, 2011
- Pazopanib: Clinical development of a potent anti-angiogenic drugCritical Reviews in Oncology/Hematology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud MorphogenesisDevelopmental Cell, 2009
- Expression of c-kit in human osteosarcoma and its relevance as a prognostic markerJournal of Clinical Pathology, 2006